X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.pharmaceutical-technology.com/news/mei-kyowa-kirin-zandelisib/
https://www.businesswire.com/news/home/20221205005800/en/MEI-Pharma-and-Kyowa-Kirin-Announce-Discontinuation-of-Zandelisib-Development-Outside-of-Japan-Following-Recent-FDA-Meeting
https://www.biopharmadive.com/news/mei-kyowa-kirin-zandelisib-FDA-new-trial-accelerated-approval/621042/
https://www.fiercebiotech.com/biotech/mei-bayer-and-gilead-its-sights-posts-pivotal-data-blood-cancer-prospect
https://www.businesswire.com/news/home/20211110005591/en/MEI-Pharma-and-Kyowa-Kirin-receive-Orphan-Drug-Designation-for-Zandelisib-for-the-Treatment-of-Follicular-Lymphoma
https://www.prnewswire.com/news-releases/mei-pharma-and-kyowa-kirin-announce-first-patient-dosed-in-the-phase-3-coastal-study-evaluating-zandelisib-plus-rituximab-in-relapsed-or-refractory-indolent-non-hodgkins-b-cell-lymphoma-301356525.html
https://www.prnewswire.com/news-releases/mei-pharma-and-kyowa-kirin-announce-first-patient-with-marginal-zone-lymphoma-dosed-in-expanded-global-phase-2-tidal-study-evaluating-zandelisib-301306621.html
https://www.prnewswire.com/news-releases/mei-pharma-announces-expansion-of-phase-1b-study-evaluating-zandelisib-and-clinical-pipeline-update-301199577.html
Market Place
Share 
